Physician profile
Daniel B Driscoll
NPI 1790970291
$21,410.82
in general payments reported to CMS, 2019-2025
27 companies · $5,202 in 2025
The $5,202 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $335 · 2021: $552 · 2022: $2,546 · 2023: $2,032 · 2024: $9,347 · 2025: $5,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,221 · Travel and Lodging: $6,511 · Consulting Fee: $2,717 · Entertainment: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,221.01 |
| Travel and Lodging | $6,510.78 |
| Consulting Fee | $2,717.00 |
| Entertainment | $132.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $11,609.61 | 2019-2025 | Clareon, Centurion, Argos |
| Regeneron Healthcare Solutions, INC. | $2,325.58 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $1,663.98 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Alphagan P |
| Glaukos Corporation | $1,348.68 | 2022-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Mallinckrodt Hospital Products INC. | $613.28 | 2022-2025 | Acthar |
| Sight Sciences, INC. | $577.72 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tersera Therapeutics LLC | $545.00 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $416.11 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $323.90 | 2022-2025 | Vyzulta, Prolensa, Xiidra |
| Genentech USA, INC. | $294.76 | 2019-2025 | Vabysmo |
| Amgen INC. | $267.46 | 2024-2025 | Tepezza |
| Allergan, INC. | $264.59 | 2019-2022 | |
| Horizon Therapeutics Plc | $232.06 | 2022-2023 | Tepezza |
| Dompe US, INC. | $197.37 | 2023-2025 | Oxervate |
| Optos, INC. | $171.36 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $156.34 | 2019-2025 | Cequa |
| Shire North American Group INC | $94.05 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $63.51 | 2019 | |
| Ocular Therapeutix, INC. | $50.00 | 2021 | |
| Ani Pharmaceuticals, INC. | $31.77 | 2024 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $27.47 | 2025 | Xdemvy |
| Coopervision INC. | $27.43 | 2023 | Misight Contact Lens |
| Coherus Oncology, INC. | $25.92 | 2023 | |
| Sandoz INC. | $23.04 | 2024 | Cimerli |
| Oyster Point Pharma, INC. | $22.89 | 2024 | Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Iridex Corporation | $17.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Driscoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.